Stada Arzneimi Namen (STDAF) 34.2500 $STDAF Pediculosis

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Stada Arzneimi Namen (STDAF) 34.2500 $STDAF

Pediculosis (Head Lice Infestation) - Global Clinical Trials Review, H1, 2015
M2 - Mon Jul 27, 6:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v2bdrs/pediculosis_head) has announced the addition of the "Pediculosis (Head Lice Infestation) Global Clinical Trials Review, H1, 2015" report to their offering. "Pediculosis (Head Lice Infestation) Global Clinical Trials Review, H1, 2015" provides data on the Pediculosis (Head Lice Infestation) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Pediculosis (Head Lice Infestation). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Pediculosis (Head Lice Infestation). Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Pediculosis (Head Lice Infestation) Therapeutics Clinical Trials - Hatchtech Pty, Ltd - ParaPRO LLC - Stada Arzneimittel AG - Sun Pharmaceutical Industries Limited - Sanofi - Summers Laboratories Incorporated - Oystershell NV - Lybar, a.s. - EctoPharma Ltd. - Altman Biomedical Consulting Pty. Ltd - Mandacaru Foundation - Shiraz University of Medical Sciences - Assistance Publique Hopitaux De Marseille - Australian National University - Centers for Disease Control and Prevention - Hackensack University Medical Center - Royal Free London NHS Foundation Trust - South Florida Family Health And Research Centers - Tokyo University of Science For more information visit http://www.researchandmarkets.com/research/v2...losis_head

Global Biosimilar Market Outlook 2020 - Market is expected to reach US$ 25.53 Billion by 2020, growing at an impressive CAGR of 54.4%
M2 - Thu Apr 16, 6:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6c6gpz/global_biosimilar) has announced the addition of the "Global Biosimilar Market Outlook 2020" report to their offering. The market, which was worth US$ 1.89 Billion in 2014, is expected to reach US$ 25.53 Billion by 2020, growing at an impressive CAGR of 54.4% The much awaited biosimilars have finally entered the US pharmaceutical market with the FDA approval of Sandoz's Zarxio, a G-CSF. The move is being hailed by biosimilar manufacturers and is expected to fuel numerous submissions in the coming days, making US a significant region for biosimilar activity. At the same time, as shrinking budgets are rooting for reduced healthcare expenditures and majority of blockbuster drugs are about to lose exclusivity, the biosimilar industry stands as the sole gainer. In the report, industry has been segmented based on the different classes of biosimilars available in the market, such as, mAbs, Insulin, Erythropoeitin (EPOs), Human Growth Hormone (HGH) and Interferons. The second segmentation divides the industry on the basis of major geographies which includes Europe, Asia-Pacific, and Others (including the US, Latin America and Middle-Eastern countries). The market is subjected to various drivers as well as challenges, which have, and will continue to mould it. It is expected that the constricting healthcare budgets, approaching patent cliff and low cost of biosimilars will serve as the major drivers for the market. However, issues associated with manufacturing capabilities, litigation risks, high cost of development and substitutability may act as bottlenecks for the industry. The report talks about the various applications and technological trends that have emerged in the past few years. This report also highlights key players and their current market share in the biosimilar domain. For every player, a brief business overview, geographic revenue break up, segment wise revenue break up, along with key financials, have been provided. A strength and weakness analysis of every player has also been presented to assist the investors in developing an understanding of the strategies of the players. At the end, a section has been dedicated to the future outlook. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the biosimilars industry. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Biologics Market Outlook to 2020 4. Global Biosimilars Market Outlook 2020 5. Market Drivers and Challenges 6. Market Trends and Developments 7. Mergers and Acquisitions 8. Porters Five Forces Model 9. Competitive Landscape 10. Future Outlook Companies Mentioned - Biocad - Celltrion - Dong-A Pharmaceutical Co., Ltd - Hospira - Intas - Sandoz - Stada Arzneimittel - Teva For more information visit http://www.researchandmarkets.com/research/6c...biosimilar

The Corporate Reputation of Pharma - The Global Patient Perspective in 2014
M2 - Thu Apr 16, 6:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mv4rwp/the_corporate) has announced the addition of the "The Corporate Reputation of Pharma - The Patient Perspective in 2014 - Global Edition " report to their offering. The Corporate Reputation of Pharmafrom a Patient Perspective' is now in its fourth edition. This report contains the latest version (2014 results; published early 2015). For each annual Corporate Reputation report, the author surveys a large number of patient groups worldwideinternational, national, and regional, from across many different disease and healthcare specialties. 1,150 patient groups from 58 countries participated in the Corporate Reputation's 4th edition. About the questionnaire: The methodology for assessing pharma corporate reputation from a patient perspective was first established by PatientView in 2010 following consultations with pharma, medical-device companies, tradesbodies and patient groups. The resulting questionnaire combines the priorities of patient groups (which have a better understanding of pharma than individual patients) and industry on the topic of corporate reputation. The same questions on corporate reputation are posed to respondent patient groups every year (though each year's respondent patient groups are not necessarily the same as those of the previous year). The answers help define what patients require from pharma companies, while acknowledging what pharma itself thinks it is capable of delivering. Since the questions do not deviate, the Corporate Reputation of Pharma allows the performance of individual pharma companies (and the industry as a whole) to be compared year on yearwhich, in turn, helps define appropriate strategies for improvement. I was torn between ethical, transparency, and patient safety. But, ultimately, patient safety is the most important to me and to our organization Global, US-based patient group focusing on cancer and palliative care Key Topics Covered: - Introduction - Understanding The Results - Methodology - Appendices: - Reputation of Pharma in 2014 - Rankings of 37 Companies - Profiles of 37 Companies - Profile of Respondents Companies Mentioned - AbbVie - Actavis - Allergan - Amgen - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer- Ingelheim - Bristol-Myers Squibb - Celgene - Eisai - Eli Lilly - GSK - Gilead - Gr?nenthal - Ipsen - Janssen - Lundbeck - Menarini - Merck & Co - Mylan - Novartis - Novo Nordisk - Otsuka - Pfizer - Roche - Sanofi - Servier - Shire - Stada Arzneimittel - Takeda - Teva - UCB For more information visit http://www.researchandmarkets.com/research/mv..._corporate
AGN: 274.84 (-1.32), BIIB: 269.16 (-10.72), NVO: 54.61 (-0.12), BAX: 33.21 (-0.04), MRK: 50.95 (-0.07), AMGN: 149.59 (-0.31), LLY: 86.14 (+2.37), BMY: 61.44 (+0.93), NVS: 91.90 (-0.71), CELGZ: 1.74 (+0.04)

Stada Arzneimittel's (STDAF) CEO Hartmut Retzlaff on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Mar 26, 9:28PM CDT


Stada: Russia-Discount Gives This Drug Maker 17% Immediate Upside
Dieter Plas - at Seeking Alpha - Thu Dec 04, 2:53PM CST


Europe Biosimilars Market & Pipeline Insight 2014
M2 - Tue Oct 07, 9:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bblsk8/europe) has announced the addition of the "Europe Biosimilars Market & Pipeline Insight" report to their offering. Biosimilars have emerged as one of the most promising segment of the European pharmaceutical industry in recent years. The biosimilars segment has been experiencing a steady growth driven by patent expiration of blockbuster drugs, amenable regulatory framework, economic incentives along with favorable pricing and reimbursement policies adopted across multiple markets in Europe. The current biosimilars market is highly fragmented in nature due to their accessibility in various therapeutic categories. The European biosimilars market is divided into various categories: Granulocyte-colony stimulating factor (G-CSF or GCSF), erythropoiesis-stimulating agents (ESAs) and somatropin biosimilars, Insulin, mAbs and follitropin. The present market fragmentation is driven by the availability of particular biosimilar products which were introduced over a decade ago. These products created niche among them and resulted in inclination toward a particular segments over a period of time. One of the most promising factors responsible for the development of biosimilars market is the patent expiration of reference drugs. The European biosimilars market is experiencing tremendous growth as blockbuster biologic drugs are going off-patent. The entry of new biosimilars due to patent expiry into various therapeutic indications has created a new category for the biosimilars. For instance, Ely Lily and Boehringer Ingelheim have already got marketing authorization of their biosimilar insulin in June'2014 even as the current diabetes drug (Lantus) marketed by Sanofi will go off patent in February'2015. The competitive pricing and reimbursement policies adopted by country specific regulators are also promoting the introduction of biosimilars in European market. The newly introduced biosimilars are approximately 20-30% cheaper and hence results in high level of acceptability among patients and physicians in comparison to originator molecule. The benefits of using the biosimilars include reimbursement provided by many governments which further decreases the financial burden from the patients as result of which they do not revert to originator molecules. Europe Biosimilars Market & Pipeline Insight Report Highlights: - Biosimilars Market Overview & Trend Analysis by Country - Biosimilars Introduction Timeline in Europe - Biosimilars Development & Market Authorization Guidelines - Biosimilars Clinical Pipeline by Phase, Indication, Company & Country - Marketed Biosimilars Clinical Insight by Phase, Indication, Company & Country - Europe Biosimilars Pipeline: 93 Biosimilars - Marketed Biosimilars: 18 Biosimilars (17 Approved by EMA & 1 in Ukraine) Key Topics Covered: 1. Europe Biosimilars Market Overview 2. Europe Biosimilars Market Trend Analysis by Country 3. Biosimilars Introduction Timeline in Europe 4. Europe Biosimilars Risk Management Planning & Safety Regulation Scenario 5. Europe Biosimilars Market Dynamics 6. Future Prospectus of Biosimilars in Europe 7. Regulatory & Approval Authorities: EMA & CHMP 8. Biosimilars Development & Market Authorization Guidelines 9. Europe Biosimilars Clinical Pipeline by Phase, Indication, Company & Country 10. Marketed Biosimilars Clinical Insight by Phase, Indication, Company & Country 11. No Development Reported in Biosimilars Clinical Pipeline 12. Competitive Landscape - Apotex - Celltrion Healthcare - Finox Biotech - Hexal - Hospira - Medice Arzneimittel P?tter - Sandoz - Stada Arzneimittel - Teva Pharma For more information visit http://www.researchandmarkets.com/research/bblsk8/europe

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bacterial Breakthrough in Cancer Therapy: Game Changer?

Updated Category News Views 35

Blurring Lines Between Bugs and Biotech Well, wouldn't you know it, the eggheads over at Jeonbuk National University in South Korea are at it again, pushing the boundaries of what these little bacterial buggers can do. This time, they’ve had a crack at cancer therapy, using engineered Salmonella to pack a double punch against breast cancer in mice. Now, if that ain't...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 234

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 147

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Medtronic's Bold Move to Own Carotid Market Full-Scale

Updated Category News Views 143

When a giant like Medtronic makes a move, you can bet investors take notice, and this latest acquisition is no exception. They’re reaching into their deep pockets to acquire Contego Medical, a company shaking up the world of carotid artery disease treatments. It’s a tactical strike to solidify their leadership in cardiovascular solutions. Medtronic's Bet on Innovation...

Continue Reading
Webull Faces FINRA Fine and Legal Battle Ahead

Updated Category News Views 45

Webull's Compliance Headache Webull’s been knocked around again. This time, the Financial Industry Regulatory Authority (FINRA) slapped it with a hefty $4.2 million fine. Talk about a hit to the wallet! It all boils down to them failing to roll out some basic anti-money laundering (AML) and other crucial compliance programs. This is no small oversight, and it's got...

Continue Reading
Gwen Stefani Kicks Off OCVIBE's New Concert Hall

Updated Category News Views 116

A Homecoming Steeped in Nostalgia Orange County’s about to do a serious throwback, folks! Gwen Stefani is set to headline the opening concert at OCVIBE's spanking new concert hall in Anaheim on March 17, 2027. Curious choice for their opener? Hardly. This gal's practically woven into the county’s tapestry—her roots run deep here, enough to make even the casual music...

Continue Reading
Mining Equipment Market to Surge, Hitting $42.81B by 2033

Updated Category News Views 98

Forecasts on Market Growth: A Robust Climb Ahead Brace yourself because this mining equipment racket is ramping up like you wouldn't believe. Analysts are telling us the market's supposed to roar from a $28.42 billion check in 2026 to a jaw-dropping $42.81 billion come 2033. That's a 6.0% CAGR—a figure that'll catch the eye of anyone not sound asleep at the wheel....

Continue Reading
WHP Global's Japan Move: A Major Toy Market Play

Updated Category News Views 35

New Horizons for Toys"R"Us in Japan Well, folks, look who's back in the toy game with a vengeance! WHP Global is shaking hands with Pan Pacific International Holdings (PPIH) to breathe new life into Toys"R"Us across Japan. Now PPIH isn’t just any player. We're talking about Japan's fourth-largest retailer, helming giants like Don Quijote and aiming to crown itself as...

Continue Reading
Lear Gears Up for Goldman Sachs Event Spotlight

Updated Category News Views 10

Lear Prepares for the Big Stage in London Autumn leaves and industry insights are falling in full swing as Lear Corporation gets its ducks in a row for the upcoming Goldman Sachs 18th Annual Industrials & Autos Week. Kicking off on December 3, 2026, this gathering in London isn't just another checkbox on their corporate calendar—it's a prime moment in the spotlight....

Continue Reading
Ballard's Q3 2026: Navigating Losses and Bold Moves

Updated Category News Views 80

Ballard’s Financial Puzzles in Q3 2026 Riding the rough waters of the third quarter in 2026, Ballard Power Systems set out its stall with some eyebrow-raising numbers. This ain't the bustling diner vibe we normally see for a thriving business. The results paint a cautious picture sprinkled with strategic shifts that demand a keen eye. GeoPura Acquisition: A Strategic...

Continue Reading

Top 5 Most Recently Viewed Articles

U.S. Industrial Production Unexpectedly Declines, Impacting Growth

Updated Category News Views 62

U.S. Industrial Production Experiences a Notable Decline The latest report reveals that U.S. industrial production has faced an unexpected decline, recorded at -0.3%. This drop highlights the ongoing struggles within the manufacturing, mining, and utility sectors. Disappointing Performance Against Expectations When comparing the -0.3% figure to a predicted decrease of...

Continue Reading
MAXHUB Partners with Microsoft to Enhance Teams Rooms Experience

Updated Category News Views 363

MAXHUB Collaborates with Microsoft to Enhance Teams In an exciting development within the tech landscape, MAXHUB is teaming up with Microsoft in an initiative aimed at improving the security and reliability of Microsoft Teams Rooms. This partnership aligns with MAXHUB's vision of leading in integrated commercial display and unified communications solutions, providing...

Continue Reading
US Dollar Strengthens While Global Markets Face Turmoil

Updated Category News Views 486

US Dollar's Rise Amid Trade Tensions In an unexpected turn of events, the US dollar has extended its gains following President Trump's announcement of new tariffs. As the global markets react to these developments, we dive into the implications for various economies and asset classes. The latest updates indicate that the 25% tariffs on imports from Canada and Mexico,...

Continue Reading
Understanding Your Rights as a Perrigo Company Shareholder

Updated Category News Views 135

Understanding Your Rights as a Perrigo Company Shareholder Shareholders of Perrigo Company plc (NYSE: PRGO) should stay informed about recent developments regarding potential securities law violations. The underlying issues stem from allegations that the company misled investors regarding its infant formula business, which has drawn significant scrutiny. Allegations...

Continue Reading
Spring Surprises: White Castle Unveils Exciting Deals Ahead

Updated Category News Views 521

Spring Promotions at White Castle As the season transforms, White Castle, the pioneering fast-food restaurant known for its Original Slider, unveils enticing deals for its loyal customers. Embracing longer days and warmer weather, the company is determined to deliver exceptional savings for all cravings this spring. Celebrating with Value-Driven Offers White Castle is...

Continue Reading